Health-related Quality of Life Among Prostate Cancer Survivors with Metastatic Disease and Non-metastatic Disease and Men Without a Cancer History in the USA

Overview

Journal J Cancer Surviv

Specialty Oncology

Date 2023 Dec 15

PMID 38102521

Authors

Zhiyuan Zheng

Kewei Sylvia Shi

Arif Kamal

David H Howard

Michal Horny

Thomas B Richards

Donatus U Ekwueme

K Robin Yabroff

Affiliations

Soon will be listed here.

Abstract

Background: Few studies have comprehensively compared health-related quality of life (HRQoL) between metastatic prostate cancer survivors, survivors with non-metastatic disease, and men without a cancer history.

Methods: We used the Surveillance, Epidemiology, and End Results-Medicare Health Outcomes Survey (SEER-MHOS) data linkage to identify men aged ≥ 65 years enrolled in Medicare Advantage (MA) plans. Prostate cancer survivors were diagnosed between 1988 and 2017 and completed MHOS surveys between 1998 and 2019. We analyzed data from 752 metastatic prostate cancer survivors (1040 survey records), 19,583 localized or regional prostate cancer survivors (non-metastatic; 30,121 survey records), and 784,305 men aged ≥ 65 years without a cancer history in the same SEER regions (1.15 million survey records). We used clustered linear regressions to compare HRQoL measures at the person-level using the Veterans RAND 12 Item Health Survey (VR-12) T-scores for general health and physical and mental component summaries.

Results: Compared to men without a cancer history, prostate cancer survivors were older, more likely to be married, and had higher socioeconomic status. Compared to men without a cancer history, metastatic prostate cancer survivors reported lower general health (T-score differences [95% confidence interval]: - 6.26, [- 7.14, - 5.38], p < .001), physical health (- 4.33, [- 5.18, - 3.48], p < .001), and mental health (- 2.64, [- 3.40, - 1.88], p < .001) component summaries. Results were similar for other VR-12 T-scores. In contrast, non-metastatic prostate cancer survivors reported similar VR-12 T-scores as men without a cancer history. Further analyses comparing metastatic and non-metastatic prostate cancer survivors support these findings.

Conclusion: Interventions to improve health-related quality of life for men diagnosed with metastatic prostate cancer merit additional investigation.

Implications For Cancer Survivors: Interventions to improve health-related quality of life for metastatic prostate cancer survivors merit additional investigation.

Citing Articles

Latent profile analysis of fear of cancer recurrence in patients with prostate cancer: Insights into risk factors and psychological interventions.

Qi Z, Dai Y, Hou S, Zhu B, Wang W Asia Pac J Oncol Nurs. 2025; 12:100651.

PMID: 39995610 PMC: 11848108. DOI: 10.1016/j.apjon.2024.100651.

Maladaptive coping styles moderate the relationship between information on cancer treatment and psychosocial symptoms: an Italian multicenter study.

Zerbinati L, Folesani F, Caruso R, Belvederi Murri M, Nanni M, Righetti S Front Psychol. 2024; 15:1338193.

PMID: 38966736 PMC: 11223643. DOI: 10.3389/fpsyg.2024.1338193.

Feng Y, Su M, Liu Y, Peng J, Sun X Support Care Cancer. 2024; 32(2):124.

PMID: 38252273 DOI: 10.1007/s00520-024-08315-7.

References

Menges D, Yebyo H, Sivec-Muniz S, Haile S, Barbier M, Tomonaga Y . Treatments for Metastatic Hormone-sensitive Prostate Cancer: Systematic Review, Network Meta-analysis, and Benefit-harm assessment. Eur Urol Oncol. 2022; 5(6):605-616. DOI: 10.1016/j.euo.2022.04.007. View

Wenzel M, Wurnschimmel C, Nocera L, Colla Ruvolo C, Tian Z, Shariat S . Overall Survival After Systemic Treatment in High-volume Versus Low-volume Metastatic Hormone-sensitive Prostate Cancer: Systematic Review and Network Meta-analysis. Eur Urol Focus. 2021; 8(2):399-408. DOI: 10.1016/j.euf.2021.04.003. View

Selim A, Rogers W, Fleishman J, Qian S, Fincke B, Rothendler J . Updated U.S. population standard for the Veterans RAND 12-item Health Survey (VR-12). Qual Life Res. 2008; 18(1):43-52. DOI: 10.1007/s11136-008-9418-2. View

Schalet B, Rothrock N, Hays R, Kazis L, Cook K, Rutsohn J . Linking Physical and Mental Health Summary Scores from the Veterans RAND 12-Item Health Survey (VR-12) to the PROMIS(®) Global Health Scale. J Gen Intern Med. 2015; 30(10):1524-30. PMC: 4579239. DOI: 10.1007/s11606-015-3453-9. View

Donovan J, Hamdy F, Lane J, Mason M, Metcalfe C, Walsh E . Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med. 2016; 375(15):1425-1437. PMC: 5134995. DOI: 10.1056/NEJMoa1606221. View

Macefield R, Jacobs M, Korfage I, Nicklin J, Whistance R, Brookes S . Developing core outcomes sets: methods for identifying and including patient-reported outcomes (PROs). Trials. 2014; 15:49. PMC: 3916696. DOI: 10.1186/1745-6215-15-49. View

Temel J, Jackson V, Billings J, Dahlin C, Block S, Buss M . Phase II study: integrated palliative care in newly diagnosed advanced non-small-cell lung cancer patients. J Clin Oncol. 2007; 25(17):2377-82. DOI: 10.1200/JCO.2006.09.2627. View

Mager R, Savko O, Bohm K, Thomas A, Dotzauer R, Borgmann H . Comparative assessment of docetaxel for safety and efficacy between hormone-sensitive and castration-resistant metastatic prostate cancer. Urol Oncol. 2019; 37(12):999-1005. DOI: 10.1016/j.urolonc.2019.07.005. View

Jones 3rd N, Jones S, Miller N . The Medicare Health Outcomes Survey program: overview, context, and near-term prospects. Health Qual Life Outcomes. 2004; 2:33. PMC: 479698. DOI: 10.1186/1477-7525-2-33. View

10.

Morgans A, Chen Y, Sweeney C, Jarrard D, Plimack E, Gartrell B . Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer. J Clin Oncol. 2018; 36(11):1088-1095. PMC: 5891128. DOI: 10.1200/JCO.2017.75.3335. View

11.

Lardas M, Liew M, VAN DEN Bergh R, De Santis M, Bellmunt J, Van den Broeck T . Quality of Life Outcomes after Primary Treatment for Clinically Localised Prostate Cancer: A Systematic Review. Eur Urol. 2017; 72(6):869-885. DOI: 10.1016/j.eururo.2017.06.035. View

12.

Chen R, Rumble R, Loblaw D, Finelli A, Ehdaie B, Cooperberg M . Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement. J Clin Oncol. 2016; 34(18):2182-90. DOI: 10.1200/JCO.2015.65.7759. View

13.

Holm M, Doveson S, Lindqvist O, Wennman-Larsen A, Fransson P . Quality of life in men with metastatic prostate cancer in their final years before death - a retrospective analysis of prospective data. BMC Palliat Care. 2018; 17(1):126. PMC: 6278096. DOI: 10.1186/s12904-018-0381-6. View

14.

Shevach J, Weiner A, Morgans A . Quality of Life-Focused Decision-Making for Prostate Cancer. Curr Urol Rep. 2019; 20(10):57. DOI: 10.1007/s11934-019-0924-2. View

15.

Bhojani N, Perrotte P, Jeldres C, Suardi N, Hutterer G, Shariat S . The effect of comorbidities and socioeconomic status on sexual and urinary function in men undergoing prostate cancer screening. J Sex Med. 2008; 5(3):668-76. DOI: 10.1111/j.1743-6109.2007.00722.x. View

16.

Mistry N, Raza S, Siddiqui S . Analysis of Inpatient Palliative Care Consultations for Patients With Metastatic Prostate Cancer. Am J Hosp Palliat Care. 2019; 37(2):136-141. DOI: 10.1177/1049909119864576. View

17.

LeMasters T, Madhavan S, Sambamoorthi U, Kurian S . A population-based study comparing HRQoL among breast, prostate, and colorectal cancer survivors to propensity score matched controls, by cancer type, and gender. Psychooncology. 2013; 22(10):2270-82. PMC: 4892175. DOI: 10.1002/pon.3288. View

18.

Pham K, Cullen J, Hurwitz L, Wolff E, Levie K, Odem-Davis K . Prospective Quality of Life in Men Choosing Active Surveillance Compared to Those Biopsied but not Diagnosed with Prostate Cancer. J Urol. 2016; 196(2):392-8. DOI: 10.1016/j.juro.2016.02.2972. View

19.

Kretschmer A, van den Bergh R, Martini A, Marra G, Valerio M, Tsaur I . Assessment of Health-Related Quality of Life in Patients with Advanced Prostate Cancer-Current State and Future Perspectives. Cancers (Basel). 2022; 14(1). PMC: 8749907. DOI: 10.3390/cancers14010147. View

20.

Siegel R, Miller K, Fuchs H, Jemal A . Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1):7-33. DOI: 10.3322/caac.21708. View